Condition: Metastatic Tumor · Sponsor: David Palma
This study is a phase III multi-institutional randomized trial. Patients will be randomized in a 1:2 ratio between current standard of care treatment (Arm 1) vs. standard of care treatment + SABR (Arm 2) to sites of known disease. Patients will be stratified by two of the strongest prognostic factors, based on a large multi-institutional analysis3: histology (Group 1: hormone-sensitive prostate cancer, breast, or renal; Group 2: all others), and number of metastases (Group 1: 1-3; Group 2: 4-10).
This description comes directly from the study's public registry record.
David Palma, MD, PhD · 519-685-8650 · David.Palma@lhsc.on.ca
Always discuss trial participation with your own doctor first.
| BC Cancer - Centre for the North | Prince George, British Columbia, Canada | Not Yet Recruiting |
| BC Cancer - Vancouver | Vancouver, British Columbia, Canada | Recruiting |
| London Regional Cancer Program of the Lawson Health Research Institute | London, Ontario, Canada | Recruiting |
| Centre Hospitalier de l'Université de Montréal-CHUM | Montreal, Quebec, Canada | Recruiting |
| Universitätsspital Zürich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05717166